呼吸器流体におけるウマヘルペスウイルス-2の診断のための定量的PCR法の開発と検証

Executive Industry Relevance

This protocol establishes a standardized quantitative PCR method for equid herpesvirus-2 detection in respiratory fluids, addressing the need for harmonized viral load quantification across laboratories. By incorporating full method validation from extraction to amplification per AFNOR NF U47-600, it reduces inter-laboratory variability and supports reliable comparative diagnostics. The approach enables predictive confidence in viral burden assessment, informing go/no-go decisions in equine respiratory disease research and therapeutic development pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of viral load dynamics as a biomarker for respiratory disease pathogenesis in equine models.
• Operational Value: Provides specific and sensitive quantification of EHV-2 genome copies, supporting mechanistic de-risking of host-pathogen interaction studies.

Screening & Assay Development

• Scientific Value: Delivers quantitative outputs with defined limit of detection and linearity range, enabling reliable compound screening against viral replication.
• Operational Value: Standardized extraction and amplification workflow ensures reproducibility across plate-based formats for high-throughput applications.

Translational & Preclinical Research

• Scientific Value: Viral genome load results in international units (IU) facilitate cross-study comparison and translational biomarker alignment in preclinical efficacy studies.
• Operational Value: Validation of the whole analytical method supports risk-adjusted advancement decisions by accounting for extraction-related variability.

Pipeline & Workflow Integration

The method fits within the discovery continuum from early target validation through preclinical evaluation, where quantitative viral load measurement informs mechanistic understanding and therapeutic intervention assessment.

• Discovery Biology: Supports hypothesis testing regarding viral load thresholds associated with respiratory disease phenotypes in equine models.
• Screening: Enables assay-ready biological systems with standardized nucleic acid extraction for consistent compound evaluation.
• Analytics: Provides threshold cycle measurements and standard curve-derived copy numbers for quantitative comparison across experimental conditions.
• Translational Research: Connects discovery-phase viral load data to preclinical validation through internationally comparable IU measurements.
• Enterprise Reuse: The validated workflow serves as a reusable platform for respiratory virus quantification beyond EHV-2, applicable to other equine pathogens.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in viral quantification reduces mechanistic ambiguity in respiratory disease models.
• Operational Value: Standardization per AFNOR norm ensures reproducibility and scalability across laboratory settings.
• Strategic Value: Accurate viral load data improves go/no-go decisions by reducing false negatives in antiviral screening.
• Portfolio Impact: Risk-adjusted prioritization of candidates based on dose-response relationships with quantified viral burden.

Implementation Considerations

• Requires expertise in molecular diagnostics and real-time PCR instrumentation.
• Dependent on access to silica column-based extraction kits and calibrated thermocyclers.
• Necessitates standardized operating procedures for contamination control when handling plasmid standards.
• Adaptation to alternative sample types (e.g., blood, tissue) would require re-validation of extraction efficiency.
• Practical limitation: Plasmid dilution series must be prepared in a contamination-controlled area to maintain quantification accuracy.

Biopharma FAQs